Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

NCT05602207 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Abrocitinib

Sponsor

Innovaderm Research Inc.